We are using the breakthrough gene silencing technology called RNA interference (RNAi), to target the growth and drug resistance of cancer cells.
The aim of the immunology programme is to use antibody-based therapeutics to target Zyrogen, a proprietary growth factor that has been implicated in the development of autoimmune and bone disorders.
[Home]
